Abstract: The invention relates to the detection and quantification of cyclopropylindole based synthetic cannabinoids UR-144 and XLR-11 by providing antibodies based on novel immunogens. These antibodies can be incorporated into methods and kits for the detection of UR-144, XLR-11 and their metabolites.
Type:
Grant
Filed:
October 30, 2013
Date of Patent:
July 14, 2015
Assignee:
RANDOX LABORATORIES LIMITED
Inventors:
Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
Abstract: The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.
Type:
Application
Filed:
December 3, 2012
Publication date:
May 7, 2015
Applicant:
RANDOX LABORATORIES LTD.
Inventors:
John Lamont, Ivan Mc Connell, Peter Fitzgerald
Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
Type:
Grant
Filed:
December 20, 2011
Date of Patent:
December 9, 2014
Assignee:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
Abstract: The invention describes epistatic interactions between single nucleotide polymorphisms on genes associated with blood pressure and provides an application for their use in a method to determine an individual's susceptibility to hypertension and hence whether anti-hypertensive treatment will be beneficial for said individual. In addition gene expression levels are also linked to blood pressure and may also be used to determine susceptibility to hypertension.
Type:
Application
Filed:
December 21, 2012
Publication date:
November 13, 2014
Applicant:
RANDOX LABORATORIES LTD.
Inventors:
Sophie Visvikis-Siest, Said El Shamieh, Helena Murray, John Lamont, Peter Fitzgerald
Abstract: The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques.
Type:
Grant
Filed:
July 16, 2010
Date of Patent:
October 7, 2014
Assignee:
Randox Laboratories Ltd.
Inventors:
Elouard Benchikh, Stephen Peter Fitzgerald, Philip Andrew Lowry, Ivan Robert McConnell
Abstract: The invention relates to the detection and quantification of cyclopropylindole based synthetic cannabinoids UR-144 and XLR-11 by providing antibodies based on novel immunogens. These antibodies can be incorporated into methods and kits for the detection of UR-144, XLR-11 and their metabolites.
Type:
Application
Filed:
October 30, 2013
Publication date:
September 25, 2014
Applicant:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
Abstract: The invention relates to the field of drug detection and describes antibody-based components methods and kits for the detection and quantification of alkaloids of the plant kratom. The invention is underpinned by novel antibodies which specifically bind to mitragynine alkaloids found in the kratom plant and their metabolites.
Type:
Application
Filed:
February 19, 2014
Publication date:
August 28, 2014
Applicant:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
Abstract: The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methyphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies.
Type:
Application
Filed:
February 21, 2014
Publication date:
August 28, 2014
Applicant:
RANDOX LABORATORIES LIMITED
Inventors:
Philip Lowry, Elouard Benchikh, Ivan McConnell, Peter Fitzgerald
Abstract: The invention describes antibodies that bind venlafaxine and O-desmethylvenlafaxine. The antibodies are derived from novel haptens and immunogens and are used in methods and kits to detect and quantify venlafaxine and O-desmethylvenlafaxine. The invention also describes novel detecting agents which can be used in the methods and kits of the invention.
Abstract: The invention relates to the detection and quantification of carbamazepine drugs and their metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.
Type:
Grant
Filed:
June 18, 2012
Date of Patent:
May 27, 2014
Assignee:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Andrew Philip Lowry, Ivan McConnell, Peter Stephen Fitzgerald
Abstract: The immunoassay method and kit are provided for the detection and/or the determination of zolpidem. The disclosure provides novel antibodies, derived from a novel immunogen, that are highly sensitive and bind to zolpidem and its main urinary metabolite [3-(2-N,N-dimethylamino-2-oxoethyl)-6-methylimidazo[1,2-a]pyridin-2-yl]benzoic acid, enabling an extension of the detection window of zolpidem in individuals who have abused the drug, or have been victim of its side-effects or its criminal misuse.
Type:
Grant
Filed:
February 1, 2011
Date of Patent:
March 18, 2014
Assignee:
Randox Laboratories Limited
Inventors:
Stephen Peter Fitzgerald, Robert Ivan McConnell, Philip Andrew Lowry, Elouard Benchikh
Abstract: The disclosure relates to methods of detecting bladder cancer including assaying a patient sample for the levels of certain combinations of biomarkers. The disclosure also relates to methods for determining the efficacy of a drug for the treatment of bladder cancer.
Type:
Application
Filed:
September 12, 2013
Publication date:
March 13, 2014
Applicant:
RANDOX LABORATORIES LTD.
Inventors:
Mark W. Ruddock, Cherith N. Reid, Kathleen Williamson, John V. Lamont, Stephen P. Fitzgerald
Abstract: A capacitive liquid level sensor is provided comprising a capacitive probe having a capacitance and comprising a sensing tip wherein the capacitive probe is configured such that the capacitance of the probe changes when the sensing tip is exposed to liquid. A signal generator operates to supply an electrical signal alternating between a high and low state to the capacitive probe, the electrical signal being configured such that the probe is alternately charged and discharged when the signal is high or low respectively. A comparator operates to detect the magnitude of an electrical signal across the capacitive probe and provides a first output signal value when the detected signal magnitude is greater than a predetermined threshold value and a second output signal value when the signal magnitude is less than the threshold value.
Type:
Application
Filed:
August 5, 2011
Publication date:
January 9, 2014
Applicant:
Randox Laboratories Ltd.
Inventors:
Ian Armstrong, Michael Duffy, Stephen Peter Fitzgerald
Abstract: The invention relates to a novel antibody which binds to wild type (wt) Glutathione S-transferase Omega 1 (wtGSTO1) but not to mutant (mut) GSTO1 and methods and uses based on the antibody. The antibody is based on novel haptens and immunogens.
Type:
Grant
Filed:
March 15, 2012
Date of Patent:
December 31, 2013
Assignee:
Randox Laboratories Limited
Inventors:
Peter Stephen Fitzgerald, Ivan Robert McConnell, Philip Andrew Lowry, Elouard Benchikh
Abstract: A method for ‘ruling out’ acute myocardial infarction (AMI) in a subject presenting with chest pain expected to be cardiac in nature. The method includes a) recording an Electrocardiography (ECG) reading from said subject, b) determining the amount of Heart-type Fatty acid binding protein (H-FABP) and cardiac Troponin T (cTnT) in a sample from said subject, c) comparing the results from b) to reference values for ruling out an acute Myocardial Infarction in a subject, and d) based on the results from steps a)-c) either ‘ruling out’ or ‘ruling in’ a diagnosis of acute Myocardial Infarction in said subject.
Abstract: The invention describes accurate and flexible methods and kits for conducting multi-analyte microarrays through the use of Tag-specific antibodies and analyte-specific Tag-anchored antibodies.
Type:
Application
Filed:
December 20, 2011
Publication date:
November 21, 2013
Applicant:
RANDOX LABORATORIES LIMITED
Inventors:
Stephen Peter Fitzgerald, Elouard Benchikh, Ivan McConnell, Philip Andrew Lowry
Abstract: The invention relates to an immunoassay method and kit for the indirect detection of chloral hydrate. The invention is underpinned by a novel immunogen that produces an antibody that is specific for the chloral hydrate metabolite trichloroethanol glucuronide. Detection and quantification of trichloroethanol glucuronide has important applications in clinical toxicology, drug facilitated crime, water testing and solvent exposure.
Type:
Grant
Filed:
June 29, 2011
Date of Patent:
September 10, 2013
Assignee:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
Abstract: The current invention describes novel immunogens which are used in the production of novel antibodies with unique binding properties in that they cross-react with a variety of phenylpiperazine derivatives. These antibodies enable methods and kits to detect and/or determine phenylpiperazine derivatives (for example mCPP, TFMPP and MeOPP) in an in vitro sample which are advantageous over currently available analytical methods in terms of cost, ease of use, speed and sensitivity.
Abstract: A biochip well is disclosed, including a vessel containing a well therewithin, the vessel forming at least base and side walls of the well and defining at least one aperture giving access to the well, and further including retaining means for holding a biochip at a predetermined position within the well, the well including a laterally offset region into which the biochip does not protrude when held at the predetermined position by the retaining means. Also disclosed are sealed well assemblies and apparatus and methods for opening sealed wells.
Type:
Application
Filed:
July 26, 2011
Publication date:
August 29, 2013
Applicant:
RANDOX LABORATORIES LTD.
Inventors:
Gareth Wilson, Michael Hooks, Peter Fitzgerald, John Lamont, Ivan McConnell
Abstract: The invention describes antibodies that bind molecules of the pyrrolidinophenone class of synthetic drugs. The antibodies are derived from novel chemical intermediates, haptens and immunogens and are used in methods and kits to detect and quantify pyrrolidinophenones.